H.C. Wainwright says Cara found 'best possible' partner, ups target to $24H.C. Wainwright analyst Oren Livnat said Cara Therapeutics selected the "best possible partner to maximize IV Korsuva" in signing an agreement with the Vifor/Fresenius joint venture. He views the deal as a "clear positive," stating that it brings in minimally dilutive financing, validates Korsuva, and de-risks the U.S. commercial launch. Livnat increased his price target on Cara shares to $24 from $22 and keeps a Buy rating on the stock.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. HUGE jump today though. $CARA, Cara Therapeutics, Inc. / M30 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.